Zhaoke Ophthalmology
Scope
Date
~
-
Bio & PharmaSamsung Bioepis gets EC's approval for Opuviz
South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European C...
Nov 19, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion applies for approval in US for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...
Jun 30, 2023 (Gmt+09:00)
-
Bio & PharmaKwangdong introduces new drug candidate for pediatric myopia
South Korean pharmaceutical company Kwangdong Pharmaceutical announced on Monday that it has signed a contract with Hong Kong-based Zhaoke Ophthalmo...
Mar 27, 2023 (Gmt+09:00)
-
Bio & PharmaSamsung Bioepis sees greater market for Byooviz eye disease biosimilar
NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...
Jul 18, 2022 (Gmt+09:00)
-
BiosimilarsSamsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz
Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...
Sep 23, 2021 (Gmt+09:00)
-
BiosimilarsSamsung Bioepis gets nod for sale of ophthalmology biosimilar in Europe
South Korea’s biopharmaceutical company Samsung Bioepis Co. won approval from European authorities for sale of Byooviz, its ophthalmology bios...
Aug 23, 2021 (Gmt+09:00)
language
